IGC Pharma (IGC) Accounts Payables (2011 - 2026)

IGC Pharma (IGC) has reported Accounts Payables for 16 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Accounts Payables rose 42.13% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 42.13% increase from a year earlier, with the FY2026 full-year figure at $1.3 million, up 42.13% from the prior year.
• Accounts Payables was $1.3 million for Q1 2026 at IGC Pharma, up from $1.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $1.6 million in Q3 2023 and troughed at $530000.0 in Q1 2023.
• A 5-year average of $972352.9 and a median of $890000.0 in 2022 frame the typical range for Accounts Payables.
• The widest YoY moves for Accounts Payables: up 68.14% in 2023, down 63.7% in 2023.
• Over 5 years, Accounts Payables stood at $890000.0 in 2022, then slipped by 27.19% to $648000.0 in 2023, then increased by 28.86% to $835000.0 in 2024, then gained by 21.44% to $1.0 million in 2025, then advanced by 23.77% to $1.3 million in 2026.
• The last three Accounts Payables figures came in at $1.3 million (Q1 2026), $1.0 million (Q4 2025), and $628000.0 (Q3 2025), per Business Quant data.